Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;12(13):965-981.
doi: 10.2217/imt-2020-0158. Epub 2020 Aug 5.

Romosozumab in the treatment of osteoporosis

Affiliations
Review

Romosozumab in the treatment of osteoporosis

Alexandra O Kobza et al. Immunotherapy. 2020 Sep.

Abstract

Osteoporosis is a disease characterized by weakening of the bone architecture, which leads to an increased risk of fracture. There has been interest in the development of osteoanabolic agents that can increase bone mass and reverse the deteriorating architecture of osteoporotic bone. Romosozumab is a new agent for osteoporosis that both promotes bone formation and inhibits bone resorption. It is a monoclonal antibody that inhibits the activity of sclerostin, which allows the Wnt pathway to promote osteoblastogenesis and inhibit the activity of bone-resorbing osteoclasts. In clinical trials, it has proven to be superior to other agents in terms of increasing bone mineral density and reducing the incidence of fractures. This review will highlight the pharmacology, clinical efficacy and safety profile of romosozumab and suggest where this medication may fit within our current management of osteoporosis.

Keywords: Wnt pathway; antibody therapeutics; bone formation; bone mineral density; immunotherapy; osteoporosis; romosozumab; sclerostin inhibitor.

PubMed Disclaimer

LinkOut - more resources